| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/14/2006 | US20060205729 treating rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, inflammatory bowel disease, bronchopulmonary dysplasia, and canine atopic dermatitis with uninterrupt cycles of aminopterin or salt without toxicity manifestations |
| 09/14/2006 | US20060205728 Novel scaffolds for beta-helix mimicry |
| 09/14/2006 | US20060205727 Combination therapy for endothelial dysfunction, angina and diabetes |
| 09/14/2006 | US20060205726 e.g. 2-(2-{3-acetoxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester; microsomal triglyceride transfer protein inhibitor in small intestine; antihyperlipidemic, antidiabetic agent; arteriosclerosis, coronary artery diseases, obesity |
| 09/14/2006 | US20060205725 Method for treating ocular hypertension and glaucoma |
| 09/14/2006 | US20060205724 Antagonizing nk-1 receptors inhibits consumption of substances of abuse |
| 09/14/2006 | US20060205723 5-(Substituted oxazolyl- or thiazolyl-ethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 09/14/2006 | US20060205722 Such as N-{1-[2-(1,3-dioxan-2-yl)ethyl]piperidin-4-yl}-N-(4-fluorobenzyl)-2-[4-(2-hydroxy-2-methylpropoxy)phenyl]acetamide; selective inverse agonists of 5-HT2A receptor with minimal monamine receptors subtype activity; antipsychotics with reduced side effects |
| 09/14/2006 | US20060205721 3-(Phenyl),5-(3-carmoylphenyl)-amino)-3H-V-triazolo(4,5-D)pyrimidine; bipolar disorder, antidepressants; antidiabetic agents; Alzheimer's disease; blood disorders; dementia; parkinson's disease; neurodegenerative diseases; genetic disorders; muscular disorders; antiinflammatory/anticarcinogenic agents |
| 09/14/2006 | US20060205720 such as 2-(4-chloro-phenyl)-5-cyclopentyl-1-(2-fluoro-phenyl)-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one; for treatment of eating disorders and psychological disorders |
| 09/14/2006 | US20060205719 Novel compounds having an antibacterial activity |
| 09/14/2006 | US20060205718 Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives |
| 09/14/2006 | US20060205717 For combating phytopathogenic diseases on plants and harvested food crops; pyrido(2,3-B)pyrazine and pyrido pyridazine derivatives; volatile enough to be active in the vapour phase |
| 09/14/2006 | US20060205716 Microbicidal agents |
| 09/14/2006 | US20060205715 6-(8-Pentylamino-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-nicotinamide; increase metabolic energy consumption, and reduction of weight; obesity, antidiabetic agent, eating disorders; antidepressant, anxiolytic agent |
| 09/14/2006 | US20060205714 Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof |
| 09/14/2006 | US20060205713 Antidiabetic agents; disease of glucose tolerance; insulin resistance; obesity; dyslipidemia; metabolic disorders; liver disorders; [4-(6-Phenethyloxy-pyridazin-3-yl)piperazin-1-yl]-(2-trifluoromethyl-phenyl)-methanone; stearoyl-CoA desaturase modulators |
| 09/14/2006 | US20060205712 e.g. N-[2-[4-(2-(S)-amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl -quinolin-8-yloxy-methyl)-benzensulfonamide trifluoroacetate; antiinflammatory agent; asthma, chronic bronchitis, allergic rhinitis, obstructive pulmonary disease (COPD) |
| 09/14/2006 | US20060205711 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| 09/14/2006 | US20060205710 Spiroazacyclic compounds as monoamine receptor modulators |
| 09/14/2006 | US20060205709 Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
| 09/14/2006 | US20060205708 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors |
| 09/14/2006 | US20060205707 adenosine triphosphate inhibitors used for the treatment of cancer; anticarcinogenic agents |
| 09/14/2006 | US20060205706 Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation |
| 09/14/2006 | US20060205705 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives as anticarcinogenic agent; with a metal chelating agent |
| 09/14/2006 | US20060205704 Modulation of neurodegenerative diseases through the progesterone receptor |
| 09/14/2006 | US20060205703 Stabilized steroid composition and method for its preparation |
| 09/14/2006 | US20060205702 Combinations comprising antimuscarinic agents and corticosteroids |
| 09/14/2006 | US20060205701 Solid peroral contraceptive preparations |
| 09/14/2006 | US20060205700 Non invasive method for prevention and treatment of cancer |
| 09/14/2006 | US20060205699 treatment cocktail represents a dual mode topical treatment for the skin disease psoriasis. The composition contains at least an Analgesic Agent and a Drying Agent as selected from the group disclosed herein. The agents heal psoriatic plaques by promoting the exfoliation of existing psoriatic plates |
| 09/14/2006 | US20060205698 pure antibiotic; free of isomers |
| 09/14/2006 | US20060205697 Novel betulin derivatives, preparation thereof and use thereof |
| 09/14/2006 | US20060205696 [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain |
| 09/14/2006 | US20060205695 4,4'-dithiobis-(3,3'-amino-6,6'-phenyl-1,1'-hexanesulfonic) acid; hypotensive agents for cardiovascular disorders, arterial hypertension, cardiac insufficiency and renal failure, myocardial infarction diabetic proteinuria |
| 09/14/2006 | US20060205694 topical nitrogen mustard or salts in nonaqueous vehicles or carriers, used for treating skin disorders |
| 09/14/2006 | US20060205692 1,1-and 1,2-Bisphosphonates as apoliprotein e modulators |
| 09/14/2006 | US20060205691 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
| 09/14/2006 | US20060205690 Glycosaminoglycans correct emotional dysfunctions without altering the normal state of consciousness, because of their ability to prevent or reduce the alteration (fluidity)of the extracellular matrix (ECM) in the brain; depolymerized sulfates of dermatan, chondroitin, heparin, keratin; psychosis |
| 09/14/2006 | US20060205689 BIVM (basic, immunoglobulin-like variable motif-containing) gene, transcriptional products, and uses thereof |
| 09/14/2006 | US20060205687 Azacytosine analogs and derivatives |
| 09/14/2006 | US20060205686 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| 09/14/2006 | US20060205685 Alkyl, substituted or unsubstituted ribose, or 2'-deoxyribose substituted 1,3,5-triazin-2(1H)-ones, which may be additionally substituted with alkyl, aryl, halo, amino, oxy, thio, and/or hydrazine groups; used for treating diseases such as hematological disorders and cancer |
| 09/14/2006 | US20060205684 Method of preparing 4-r-substituted 4-demethoxydaunorubicin |
| 09/14/2006 | US20060205683 Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
| 09/14/2006 | US20060205682 Antibiotic and combinations of antibiotic and symptomatic relief agent formulations |
| 09/14/2006 | US20060205679 Topical and oral formulations of cardiac glycosides for treating skin diseases |
| 09/14/2006 | US20060205678 Treatment of symptoms associated with irritable bowel syndrome |
| 09/14/2006 | US20060205677 Diammine and bis(cyclohexanediamine) complexes of platinium malonates containing glucopyranosyl, mannopyranosyl, galactopyranosyl or glucurony groups [1R,2R-Cyclohexanediamine-N, N'][{2-( beta -D-Glucopyranos-1-ylamido)ethyl}propanedioato(2-)-O,O']Platinum(II); good water solubility |
| 09/14/2006 | US20060205676 I kappa B kinase beta inhibitors that are 2-amino-4,6-disubstituted nicotinic acid ester analogs; antiinflammatory, antitumor and antiischemic effects; asthma; nuclear factor kappa B inhibitors; 7-(2-hydroxyphenyl)-5-(3-piperidinyl)-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one |
| 09/14/2006 | US20060205675 Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
| 09/14/2006 | US20060205674 Prodrugs containing novel bio-cleavable linkers |
| 09/14/2006 | US20060205672 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 09/14/2006 | US20060205671 Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury |
| 09/14/2006 | US20060205665 Non-basic amino acid sequence transporter peptide conjugated to biological effector; translocation across the membrane of eukaryotic cells |
| 09/14/2006 | US20060205662 Combination treatment with t-PA variant and low molecular weight heparin |
| 09/14/2006 | US20060205659 Peptide radical having 5-25 amino acids with its N-terminus capped with a monoester of fumaric acid; used to treat autoimmune diseases, mitochondrial diseases, and NF-kappaB mediated diseases and in transplantation medicine |
| 09/14/2006 | US20060205658 Irrigation solution and method for inhibition of pain and inflammation |
| 09/14/2006 | US20060205657 Irrigation solution and method for inhibition of pain and inflammation |
| 09/14/2006 | US20060205655 Nucleic acids encoding (poly) peptides having CHIPS activity |
| 09/14/2006 | US20060205650 Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors |
| 09/14/2006 | US20060205649 Via operably linked to Neuron Restrictive Silencing Element (NRSE) that is recognized by Neuron-Restrictive Silencing Factor (NRSF) transcriptional repressor, reducing nicotinamide adenine dinucleotide (NADH) concentrations in cell by inhibiting glycolytic enzymes such as hexokinase |
| 09/14/2006 | US20060205648 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides |
| 09/14/2006 | US20060205635 Antigene oligomers inhibit transcription |
| 09/14/2006 | US20060205634 Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| 09/14/2006 | US20060205633 Therapeutic agent for diabetes |
| 09/14/2006 | US20060205598 Compositions for protecting plants from pathogens |
| 09/14/2006 | US20060205084 Reducing toxicity associated with 6-mercaptopurine drug treatment via monitoring concentration of 6-thioguanine in blood; treating inflammatory bowel disease |
| 09/14/2006 | US20060205049 Method for the production of resveratrol in cell cultures |
| 09/14/2006 | US20060205021 Mammalian IAP gene family, primers, probes and detection methods |
| 09/14/2006 | US20060204993 Methods and compositions for modulating CHK2 pathways and methods for screening for same |
| 09/14/2006 | US20060204981 Compositions for modulation of PARP and methods for screening for same |
| 09/14/2006 | US20060204980 Colorectal cancer therapies |
| 09/14/2006 | US20060204975 Markers for cyclin dependent kinase inhibitors |
| 09/14/2006 | US20060204974 Screening agents for post-transcriptional control of angiotensin receptors; hypotensive agents |
| 09/14/2006 | US20060204966 selecting therapy for a human subject having a solid epithelial tumor that overexpresses ErbB2 comprising determining whether the tumor expresses p95ErbB2; reversible dual tyrosine kinase inhibitor of both ErbB2 and epidermal growth factor receptor |
| 09/14/2006 | US20060204599 Dietary supplement and method of using same |
| 09/14/2006 | US20060204598 Nicotine-alternative compositions and methods of producing such compositions |
| 09/14/2006 | US20060204596 Formulation of a mixture of Free-B-Ring flavonoids and flavans as a therapeutic agent |
| 09/14/2006 | US20060204592 Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions |
| 09/14/2006 | US20060204587 Use of film coating as taste-masking coating of oral dosage forms |
| 09/14/2006 | US20060204585 Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| 09/14/2006 | US20060204583 Chemoembolisation |
| 09/14/2006 | US20060204578 Dual controlled release dosage form |
| 09/14/2006 | US20060204577 Pharmaceutical Compositions of Drugs and Neutralized Acidic Polymers |
| 09/14/2006 | US20060204576 Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers |
| 09/14/2006 | US20060204575 Amphetamine formulations |
| 09/14/2006 | US20060204574 Sustained-release oral administration preparation of phenylalanine derivatives |
| 09/14/2006 | US20060204572 Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives |
| 09/14/2006 | US20060204571 Stable compositions of bupropion or its pharmaceutically acceptable salts |
| 09/14/2006 | US20060204570 Preparing method for controlled released type tablet tamsulosin hcl and the tablet thereof |
| 09/14/2006 | US20060204569 Functional starch powder |
| 09/14/2006 | US20060204568 Oral pharmaceutical preparation for proton pump antagonists |
| 09/14/2006 | US20060204564 Compositions and kits for the removal of irritating compounds from bodily surfaces |
| 09/14/2006 | US20060204563 Compositions and kits for the removal of irritating compounds from bodily surfaces |
| 09/14/2006 | US20060204561 Device for delivery of TRPV1 agonists |
| 09/14/2006 | US20060204560 Wound dressing consisting of a biodegradable biopolymer |
| 09/14/2006 | US20060204558 Antimicrobial pet wipes and methods |
| 09/14/2006 | US20060204555 Thermosensitive polymers for therapeutic use and methods of preparation |
| 09/14/2006 | US20060204552 comprising pantothenic acid, nicotinamide, histidine, inositol and choline, its use in the treatment of a canine skin disease |